1. Home
  2. AKRO vs WSFS Comparison

AKRO vs WSFS Comparison

Compare AKRO & WSFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • WSFS
  • Stock Information
  • Founded
  • AKRO 2017
  • WSFS 1980
  • Country
  • AKRO United States
  • WSFS United States
  • Employees
  • AKRO N/A
  • WSFS N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • WSFS Major Banks
  • Sector
  • AKRO Health Care
  • WSFS Finance
  • Exchange
  • AKRO Nasdaq
  • WSFS Nasdaq
  • Market Cap
  • AKRO 3.5B
  • WSFS 3.3B
  • IPO Year
  • AKRO 2019
  • WSFS N/A
  • Fundamental
  • Price
  • AKRO $40.48
  • WSFS $51.87
  • Analyst Decision
  • AKRO Strong Buy
  • WSFS Hold
  • Analyst Count
  • AKRO 9
  • WSFS 4
  • Target Price
  • AKRO $76.29
  • WSFS $63.67
  • AVG Volume (30 Days)
  • AKRO 938.9K
  • WSFS 363.6K
  • Earning Date
  • AKRO 05-09-2025
  • WSFS 04-24-2025
  • Dividend Yield
  • AKRO N/A
  • WSFS 1.16%
  • EPS Growth
  • AKRO N/A
  • WSFS 0.23
  • EPS
  • AKRO N/A
  • WSFS 4.41
  • Revenue
  • AKRO N/A
  • WSFS $984,948,000.00
  • Revenue This Year
  • AKRO N/A
  • WSFS N/A
  • Revenue Next Year
  • AKRO N/A
  • WSFS $4.04
  • P/E Ratio
  • AKRO N/A
  • WSFS $11.76
  • Revenue Growth
  • AKRO N/A
  • WSFS 6.26
  • 52 Week Low
  • AKRO $17.86
  • WSFS $41.33
  • 52 Week High
  • AKRO $58.40
  • WSFS $62.75
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 36.69
  • WSFS 44.16
  • Support Level
  • AKRO $41.84
  • WSFS $52.52
  • Resistance Level
  • AKRO $45.38
  • WSFS $53.82
  • Average True Range (ATR)
  • AKRO 1.98
  • WSFS 1.24
  • MACD
  • AKRO -0.40
  • WSFS 0.15
  • Stochastic Oscillator
  • AKRO 16.39
  • WSFS 53.24

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About WSFS WSFS Financial Corporation

WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.

Share on Social Networks: